FINWIRES · TerminalLIVE
FINWIRES

Philippines to Reissue Up to 50 Billion Peso Bonds

By

The Philippines Bureau of the Treasury said it will reissue two series of bonds worth a total of up 50 billion pesos, according to a document on the bureau's website Thursday.

Of this, 20 billion pesos to 30 billion pesos of four-year bonds carrying a 6.375% coupon rate are being issued and will mature July 27, 2030.

10 billion pesos to 20 billion pesos of 10-year bonds will also be issued, with a coupon rate of 5.925% and a maturity date of Feb. 23, 2036.

The auction date for the issue is May 26, with a settlement date of May 28.

Related Articles

Asia

C.banner International Grants 249.2 Million Options Under Incentive Scheme

C.banner International (HKG:1028) granted a little over 249.2 million options to certain grantees on Friday, according to a same-day Hong Kong bourse filing.The options are exercisable into the same number of shares, representing 10% of the clothes retailer's issued shares, at HK$0.99 apiece.Of the total, 24.9 million options each were granted to President Yuan Zhenhua and Chief Financial Officer Zhang Baojun, with the remaining 199.4 million options to 11 other employees.The firm now has no shares available for future grant under the scheme.

$HKG:1028
Asia

China Securities Regulator Penalizes Three Brokers for Illegal Overseas Stock Trading

The China Securities Regulatory Commission sanctioned three brokers for illegally facilitating overseas securities trading for domestic investors, according to a Friday statement by the watchdog.Tiger Brokers (NZ), Futu Securities International (Hong Kong), and Longbridge Securities (Hong Kong) will have their ill-gotten claims confiscated and face "severe penalties," the regulator said."Such illegal cross-border business operations have disrupted the market order and should be subjected to a heavy crackdown," the securities regulator said.CSRC's move is seen to crack down on illegal outflows and regulate market misconduct, the South China Morning Post reported separately.

$^SSEC$^SZSE
Asia

Kelun Biotech to Present Study Results of Cancer Drugs at American Oncology Meeting

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) will present the results of its registrational studies on sacituzumab tirumotecan (sac-TMT) and lunbotinib fumarate at the 2026 American Society of Clinical Oncology annual meeting, according to a filing by parent Sichuan Kelun Pharmaceutical (SHE:002422) with the Shenzhen bourse.Its study on its sacituzumab tirumotecan drug versus pembrolizumab for advanced non-small cell lung cancer treatment showed a higher response rate for its sac-TMT against pembrolizumab, the filing said.The company will also present results from its study on lunbotinib, which showed an objective response rate of 87.1% on patients with RET-fusion positive non-small cell lung cancer in patients with prior chemotherapy.

$HKG:6990$SHE:002422